RCC4
MCID: RNL034
MIFTS: 15

Renal Cell Carcinoma 4 (RCC4)

Categories: Cancer diseases, Nephrological diseases, Rare diseases

Aliases & Classifications for Renal Cell Carcinoma 4

MalaCards integrated aliases for Renal Cell Carcinoma 4:

Name: Renal Cell Carcinoma 4 20
Rcc4 20

Classifications:



Summaries for Renal Cell Carcinoma 4

MalaCards based summary : Renal Cell Carcinoma 4, also known as rcc4, is related to renal cell carcinoma, nonpapillary and kidney cancer. An important gene associated with Renal Cell Carcinoma 4 is SLC49A4 (Solute Carrier Family 49 Member 4). The drugs Sunitinib and Tyrosine have been mentioned in the context of this disorder. Affiliated tissues include pancreas, pituitary and endothelial.

Related Diseases for Renal Cell Carcinoma 4

Diseases in the Hereditary Renal Cell Carcinoma family:

Renal Cell Carcinoma 4

Diseases related to Renal Cell Carcinoma 4 via text searches within MalaCards or GeneCards Suite gene sharing:

# Related Disease Score Top Affiliating Genes
1 renal cell carcinoma, nonpapillary 10.5
2 kidney cancer 10.1
3 chronic kidney disease 9.9
4 hypoxia 9.9

Symptoms & Phenotypes for Renal Cell Carcinoma 4

Drugs & Therapeutics for Renal Cell Carcinoma 4

Drugs for Renal Cell Carcinoma 4 (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):


# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Sunitinib Approved, Investigational 557795-19-4, 341031-54-7 5329102
2
Tyrosine Approved, Investigational, Nutraceutical 60-18-4 6057

Interventional clinical trials:


# Name Status NCT ID Phase Drugs
1 The Cardiovascular Effects of Sunitinib Therapy: Off Target Changes in Cardiac Metabolism and Ventricular Vascular Mechanics (CREST) Completed NCT01370109

Search NIH Clinical Center for Renal Cell Carcinoma 4

Genetic Tests for Renal Cell Carcinoma 4

Anatomical Context for Renal Cell Carcinoma 4

MalaCards organs/tissues related to Renal Cell Carcinoma 4:

40
Pancreas, Pituitary, Endothelial

Publications for Renal Cell Carcinoma 4

Articles related to Renal Cell Carcinoma 4:

(show top 50) (show all 119)
# Title Authors PMID Year
1
Oncologic outcomes and safety of percutaneous cryoablation for biopsy-proven renal cell carcinoma up to 4 cm in diameter: a prospective observational study. 61
33174078 2021
2
Modifications on the Tetrahydroquinoline Scaffold Targeting a Phenylalanine Cluster on GPER as Antiproliferative Compounds against Renal, Liver and Pancreatic Cancer Cells. 61
33435260 2021
3
Hydroxamic acid derivatives as HDAC1, HDAC6 and HDAC8 inhibitors with antiproliferative activity in cancer cell lines. 61
32591593 2020
4
Identification of a new aggressive axis driven by ciliogenesis and absence of VDAC1-ΔC in clear cell Renal Cell Carcinoma patients. 61
32194829 2020
5
Characterization of the role of TMEM45A in cancer cell sensitivity to cisplatin. 61
31801939 2019
6
Discovery of a novel 2,5-dihydroxycinnamic acid-based 5-lipoxygenase inhibitor that induces apoptosis and may impair autophagic flux in RCC4 renal cancer cells. 61
31260889 2019
7
15-deoxy-Δ12, 14-prostaglandin J2 enhances anticancer activities independently of VHL status in renal cell carcinomas. 61
30815591 2019
8
Suppressive effects of iron chelation in clear cell renal cell carcinoma and their dependency on VHL inactivation. 61
30553971 2019
9
Type 3 inositol 1,4,5-trisphosphate receptor has antiapoptotic and proliferative role in cancer cells. 61
30796197 2019
10
Cancerous phenotypes associated with hypoxia-inducible factors are not influenced by the volatile anesthetic isoflurane in renal cell carcinoma. 61
30986231 2019
11
Shared Decision-Making for Patients with Advanced Urological Malignancies: Evaluation of a Joint Urological-Oncological Clinic Model. 61
31170721 2019
12
Scavenger receptor BI promotes cytoplasmic accumulation of lipoproteins in clear-cell renal cell carcinoma. 61
30173145 2018
13
Epiglottic mass as presenting sign of metastatic renal cell carcinoma 4 years after nephrectomy. 61
30258786 2018
14
Physcion 8-O-β-glucopyranoside inhibits clear-cell renal cell carcinoma bydownregulating hexokinase II and inhibiting glycolysis. 61
29758413 2018
15
Suppression of mitochondrial oxygen metabolism mediated by the transcription factor HIF-1 alleviates propofol-induced cell toxicity. 61
29895831 2018
16
Low tumor glutathione level as a sensitivity marker for glutamate-cysteine ligase inhibitors. 61
29928324 2018
17
Endogenous H2S producing enzymes are involved in apoptosis induction in clear cell renal cell carcinoma. 61
29793450 2018
18
Differential effects of sevoflurane on the metastatic potential and chemosensitivity of non-small-cell lung adenocarcinoma and renal cell carcinoma in vitro. 61
29406185 2018
19
RAPTOR up-regulation contributes to resistance of renal cancer cells to PI3K-mTOR inhibition. 61
29389967 2018
20
Genitourinary Malignancies in Transplant or Dialysis Patients: The Frequency of Two Newly Described 2016 World Health Organization Histopathologic Types. 61
28923625 2017
21
MicroRNA-1 and MicroRNA-21 Individually Regulate Cellular Growth of Non-malignant and Malignant Renal Cells. 61
28652429 2017
22
HIF-1-mediated suppression of mitochondria electron transport chain function confers resistance to lidocaine-induced cell death. 61
28630416 2017
23
Synthesis and anti-cancer activities of new sulfonamides 4-substituted-triazolyl nucleosides. 61
28325600 2017
24
Microwave Ablation for Lung Neoplasms: A Retrospective Analysis of Long-Term Results. 61
27993505 2017
25
Rho-associated kinase 1 inhibition is synthetically lethal with von Hippel-Lindau deficiency in clear cell renal cell carcinoma. 61
27841867 2017
26
Long-Term Outcome of Nephron-Sparing Surgery Compared to Radical Nephrectomy for Renal Cell Carcinoma ≥4 cm - A Matched-Pair Single Institution Analysis. 61
27505105 2017
27
Different Cytokine and Chemokine Expression Patterns in Malignant Compared to Those in Nonmalignant Renal Cells. 61
28775934 2017
28
SENP1 promotes proliferation of clear cell renal cell carcinoma through activation of glycolysis. 61
27741516 2016
29
Renal Cell Carcinoma Programmed Death-ligand 1, a New Direct Target of Hypoxia-inducible Factor-2 Alpha, is Regulated by von Hippel-Lindau Gene Mutation Status. 61
26707870 2016
30
Physapubescin selectively induces apoptosis in VHL-null renal cell carcinoma cells through down-regulation of HIF-2α and inhibits tumor growth. 61
27581364 2016
31
Mutant versions of von Hippel-Lindau (VHL) can protect HIF1α from SART1-mediated degradation in clear-cell renal cell carcinoma. 61
25915846 2016
32
Lung Cancer and Multiple Neoplasms: A Retrospective Analysis. 61
26987325 2016
33
Suppression of mitochondrial respiration with auraptene inhibits the progression of renal cell carcinoma: involvement of HIF-1α degradation. 61
26474388 2015
34
Induction of apoptotic cell death by betulin in multidrug-resistant human renal carcinoma cells. 61
26059173 2015
35
Identification of the Lipodepsipeptide MDN-0066, a Novel Inhibitor of VHL/HIF Pathway Produced by a New Pseudomonas Species. 61
26018559 2015
36
Pseudomonas soli sp. nov., a novel producer of xantholysin congeners. 61
25097020 2014
37
Evidence for aldosterone-dependent growth of renal cell carcinoma. 61
24802662 2014
38
Hypoxia-inducible factors are already "active" in the Von Hippel-Lindau-deficient renal cell carcinoma-4 cells. 61
24845925 2014
39
High expression of the secreted protein dickkopf homolog 4: roles in invasion and metastasis of renal cell carcinoma and its association with Von Hippel-Lindau gene. 61
24573574 2014
40
EAF2 suppresses hypoxia-induced factor 1α transcriptional activity by disrupting its interaction with coactivator CBP/p300. 61
24421387 2014
41
STAT3 and HIF1α cooperatively activate HIF1 target genes in MDA-MB-231 and RCC4 cells. 61
23604114 2014
42
Management and prevention of chylous leakage after laparoscopic lymphadenectomy. 61
25268098 2014
43
BAY 87-2243, a highly potent and selective inhibitor of hypoxia-induced gene activation has antitumor activities by inhibition of mitochondrial complex I. 61
24403227 2013
44
Isoflurane, a commonly used volatile anesthetic, enhances renal cancer growth and malignant potential via the hypoxia-inducible factor cellular signaling pathway in vitro. 61
23774231 2013
45
Clinical implications of current developments in genitourinary pathology. 61
23808460 2013
46
Retroperitoneal recurrence of a stage 1 renal cell carcinoma 4 years following core biopsy and fine needle aspiration: possible needle tract seeding. 61
22833531 2013
47
Inhibition of mTORC2 but not mTORC1 up-regulates E-cadherin expression and inhibits cell motility by blocking HIF-2α expression in human renal cell carcinoma. 61
23147251 2013
48
Retroperitoneal recurrence of a stage 1 renal cell carcinoma 4 years following core biopsy and fine needle aspiration: possible needle tract seeding. 61
22833375 2013
49
miR-210 is a target of hypoxia-inducible factors 1 and 2 in renal cancer, regulates ISCU and correlates with good prognosis. 61
23449350 2013
50
A3 adenosine receptor mediates apoptosis in in vitro RCC4-VHL human renal cancer cells by up-regulating AMID expression. 61
23174235 2013

Variations for Renal Cell Carcinoma 4

Expression for Renal Cell Carcinoma 4

Search GEO for disease gene expression data for Renal Cell Carcinoma 4.

Pathways for Renal Cell Carcinoma 4

GO Terms for Renal Cell Carcinoma 4

Sources for Renal Cell Carcinoma 4

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 05-Apr-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 Tocris
70 UMLS
71 UMLS via Orphanet
Content
Loading form....